These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1472926)

  • 1. Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.
    Lotzová E
    Leuk Lymphoma; 1992 May; 7(1-2):15-28. PubMed ID: 1472926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of MHC-nonrestricted and restricted oncolytic subsets from human bone marrow.
    Fuchshuber PR; Lotzová E; Savary CA
    Cell Immunol; 1992 Jan; 139(1):30-43. PubMed ID: 1728969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
    Savary CA; Lotzová E
    Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
    Drobyski WR; LeFever AV; Truitt RL
    Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
    Ozdemir O; Savaşan S
    Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J; Gulati SC
    Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of recombinant human IL-2 in miniature swine.
    Nakajima K; Smith CV; Mixon A; Rosengard BR; Guzzetta PC; Spitzer TR; Eckhaus MA; Sachs DH
    Transplant Proc; 1991 Feb; 23(1 Pt 1):248-50. PubMed ID: 1990524
    [No Abstract]   [Full Text] [Related]  

  • 12. Natural killer cells in haematopoietic stem cell transplantation.
    Lowdell MW
    Transfus Med; 2003 Dec; 13(6):399-404. PubMed ID: 14651745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
    Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
    Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of interleukin-2-activated killer cells of rhesus monkeys: striking resemblance to the human system.
    Savary CA; Lotzová E; Jackson HJ; Jardine JH; Ang KK
    J Leukoc Biol; 1993 Oct; 54(4):307-13. PubMed ID: 8105014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity and clinical application of activated NK cells.
    Lotzová E
    Med Oncol Tumor Pharmacother; 1989; 6(1):93-8. PubMed ID: 2786121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
    Zollner TM; Zhu HG; Anderer FA
    Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.